Octreotide capsules

DRUG3 trials

Sponsors

Chiasma, Inc.

Conditions

Acromegaly

Phase 3

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

CompletedNCT01412424

Chiasma, Inc.Acromegaly

Start: 2012-03-31End: 2014-05-31Updated: 2017-08-17

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

CompletedNCT02685709

Chiasma, Inc.Acromegaly

Start: 2016-02-29End: 2021-08-31Updated: 2022-04-22

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Chiasma, Inc.Acromegaly

Start: 2017-09-01End: 2022-05-31Updated: 2020-11-23

Related Papers

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial

Journal of the Endocrine Society2023-10-011 citations

MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly

The Journal of Clinical Endocrinology & Metabolism2023-06-1518 citations

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly

Journal of the Endocrine Society2022-11-01

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial

Journal of the Endocrine Society2022-11-01

RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase

Journal of the Endocrine Society2022-11-01

The MPOWERED Trial Comparing the Effectiveness, Safety, and Patient Experiences’ of Monthly Injections and Oral Medication Used to Treat Acromegaly

Future Rare Diseases2022-05-19

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.

2021-12-2232 citations

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.

2021-06-2513 citations

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide

The Journal of Clinical Endocrinology & Metabolism2020-08-1696 citations